Feasibility and safety of cangrelor in patients with suboptimal P2Y<inf>12</inf> inhibition undergoing percutaneous coronary intervention: The Dutch Cangrelor registry

Abi Selvarajah; Annerieke H. Tavenier; Wilbert L. Bor; Vital Houben; Saman Rasoul; Eliza Kaplan; Koen Teeuwen; Sjoerd H. Hofma; Erik Lipsic; Giovanni Amoroso; Maarten A.H. van Leeuwen; Jur M. ten Berg; Arnoud W.J. van ‘t Hof; Renicus S. Hermanides

doi:10.1093/ehjopen/oeab028

Feasibility and safety of cangrelor in patients with suboptimal P2Y<inf>12</inf> inhibition undergoing percutaneous coronary intervention: The Dutch Cangrelor registry

Abi Selvarajah, Annerieke H. Tavenier, Wilbert L. Bor, Vital Houben, Saman Rasoul, Eliza Kaplan, Koen Teeuwen, Sjoerd H. Hofma, Erik Lipsic, Giovanni Amoroso, Maarten A.H. van Leeuwen, Jur M. ten Berg, Arnoud W.J. van ‘t Hof, Renicus S. Hermanides^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Article number	1–3
Journal	European heart journal open
Volume	1
Issue number	3
DOIs	https://doi.org/10.1093/ehjopen/oeab028
Publication status	Published - 1 Nov 2021

Keywords

Cangrelor
P2Y12 inhibitors
Percutaneous coronary intervention
Platelet inhibition

Access to Document

10.1093/ehjopen/oeab028Licence: CC BY-NC

Cite this

Selvarajah, A., Tavenier, A. H., Bor, W. L., Houben, V., Rasoul, S., Kaplan, E., Teeuwen, K., Hofma, S. H., Lipsic, E., Amoroso, G., van Leeuwen, M. A. H., ten Berg, J. M., van ‘t Hof, A. W. J., & Hermanides, R. S. (2021). Feasibility and safety of cangrelor in patients with suboptimal P2Y<inf>12</inf> inhibition undergoing percutaneous coronary intervention: The Dutch Cangrelor registry. European heart journal open, 1(3), Article 1–3. https://doi.org/10.1093/ehjopen/oeab028

@article{467326a84fef4dce86b2928f7e0a91a7,

title = "Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: The Dutch Cangrelor registry",

keywords = "Cangrelor, P2Y12 inhibitors, Percutaneous coronary intervention, Platelet inhibition",

author = "Abi Selvarajah and Tavenier, {Annerieke H.} and Bor, {Wilbert L.} and Vital Houben and Saman Rasoul and Eliza Kaplan and Koen Teeuwen and Hofma, {Sjoerd H.} and Erik Lipsic and Giovanni Amoroso and {van Leeuwen}, {Maarten A.H.} and {ten Berg}, {Jur M.} and {van {\textquoteleft}t Hof}, {Arnoud W.J.} and Hermanides, {Renicus S.}",

year = "2021",

month = nov,

day = "1",

doi = "10.1093/ehjopen/oeab028",

language = "English",

volume = "1",

journal = "European heart journal open",

issn = "2752-4191",

publisher = "Oxford University Press",

number = "3",

}

Selvarajah, A, Tavenier, AH, Bor, WL, Houben, V, Rasoul, S, Kaplan, E, Teeuwen, K, Hofma, SH, Lipsic, E, Amoroso, G, van Leeuwen, MAH, ten Berg, JM , van ‘t Hof, AWJ & Hermanides, RS 2021, 'Feasibility and safety of cangrelor in patients with suboptimal P2Y<inf>12</inf> inhibition undergoing percutaneous coronary intervention: The Dutch Cangrelor registry', European heart journal open, vol. 1, no. 3, 1–3. https://doi.org/10.1093/ehjopen/oeab028

Feasibility and safety of cangrelor in patients with suboptimal P2Y<inf>12</inf> inhibition undergoing percutaneous coronary intervention: The Dutch Cangrelor registry. / Selvarajah, Abi; Tavenier, Annerieke H.; Bor, Wilbert L. et al.
In: European heart journal open, Vol. 1, No. 3, 1–3, 01.11.2021.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention

T2 - The Dutch Cangrelor registry

AU - Selvarajah, Abi

AU - Tavenier, Annerieke H.

AU - Bor, Wilbert L.

AU - Houben, Vital

AU - Rasoul, Saman

AU - Kaplan, Eliza

AU - Teeuwen, Koen

AU - Hofma, Sjoerd H.

AU - Lipsic, Erik

AU - Amoroso, Giovanni

AU - van Leeuwen, Maarten A.H.

AU - ten Berg, Jur M.

AU - van ‘t Hof, Arnoud W.J.

AU - Hermanides, Renicus S.

PY - 2021/11/1

Y1 - 2021/11/1

KW - Cangrelor

KW - P2Y12 inhibitors

KW - Percutaneous coronary intervention

KW - Platelet inhibition

U2 - 10.1093/ehjopen/oeab028

DO - 10.1093/ehjopen/oeab028

M3 - Comment/Letter to the editor

SN - 2752-4191

VL - 1

JO - European heart journal open

JF - European heart journal open

IS - 3

M1 - 1–3

ER -